Literature DB >> 28670378

Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma.

Yinuo Li1,2, Shuhua Lu3, Ying Xu2, Chunping Qiu2, Chengjuan Jin2, Yuqiong Wang1,2, Zhaojian Liu1, Beihua Kong2.   

Abstract

CD47 is an antiphagocytic signal that cancer cells employ to inhibit macrophage-mediated destruction. CD47 is overexpressed in various human malignancies. However, the expression and functional significance of CD47 in high-grade serous ovarian carcinoma (HGSOC) has not been completely understood. In this study, we reported that CD47 was commonly overexpressed in HGSOC. Higher CD47 expression was significantly correlated with poor prognosis of HGSOC patients. Functional investigations revealed that CD47 overexpression in ovarian cancer cells significantly promoted migration and invasion. Moreover, CD47 induced epithelial-mesenchymal transition (EMT) through modulating E-cadherin and N-cadherin. Our findings suggest that up-regulation of CD47 is correlated with ovarian cancer progression and it might be a potential biomarker for predicting clinical outcomes.

Entities:  

Keywords:  CD47; EMT; high-grade serous ovarian carcinoma; invasion; prognosis

Year:  2017        PMID： 28670378      PMCID： PMC5489890     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  21 in total

1.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.

Authors:  Huimin Zhang; Haiquan Lu; Lisha Xiang; John W Bullen; Chuanzhao Zhang; Debangshu Samanta; Daniele M Gilkes; Jianjun He; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-28       Impact factor: 11.205

Review 3.  Integrin-associated protein (CD47) and its ligands.

Authors:  E J Brown; W A Frazier
Journal:  Trends Cell Biol       Date:  2001-03       Impact factor: 20.808

4.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

5.  The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.

Authors:  R M Brightwell; K S Grzankowski; S Lele; K Eng; M Arshad; H Chen; K Odunsi
Journal:  Gynecol Oncol       Date:  2016-08-25       Impact factor: 5.482

6.  CD47 regulates bone mass and tumor metastasis to bone.

Authors:  Ozge Uluçkan; Stephanie N Becker; Hongju Deng; Wei Zou; Julie L Prior; David Piwnica-Worms; William A Frazier; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  A genetically defined model for human ovarian cancer.

Authors:  Jinsong Liu; Gong Yang; Jennifer A Thompson-Lanza; Armand Glassman; Kimberly Hayes; Andrea Patterson; Rebecca T Marquez; Nelly Auersperg; Yinhua Yu; William C Hahn; Gordon B Mills; Robert C Bast
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

8.  Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Authors:  Kipp Weiskopf; Aaron M Ring; Chia Chi M Ho; Jens-Peter Volkmer; Aron M Levin; Anne Kathrin Volkmer; Engin Ozkan; Nathaniel B Fernhoff; Matt van de Rijn; Irving L Weissman; K Christopher Garcia
Journal:  Science       Date:  2013-05-30       Impact factor: 47.728

9.  Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.

Authors:  Huimin Wang; Mingzi Tan; Song Zhang; Xiao Li; Jian Gao; Danye Zhang; Yingying Hao; Song Gao; Juanjuan Liu; Bei Lin
Journal:  Int J Mol Sci       Date:  2015-02-04       Impact factor: 5.923

10.  Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.

Authors:  S Knauf; R C Bast
Journal:  Int J Biol Markers       Date:  1988 Apr-Jun       Impact factor: 3.248
View more
  26 in total

1.  Centromere protein U facilitates metastasis of ovarian cancer cells by targeting high mobility group box 2 expression.

Authors:  Hongjuan Li; Hui Zhang; Yali Wang
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

2.  PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.

Authors:  Zhenlin Yang; Jiachen Xu; Renda Li; Yibo Gao; Jie He
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-14       Impact factor: 4.553

Review 3.  Targeting CD47 as a Novel Immunotherapy for Breast Cancer.

Authors:  Can Chen; Runlu Wang; Xi Chen; Yulong Hou; Jingting Jiang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

4.  Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Authors:  Amer M Zeidan; Daniel J DeAngelo; Jeanne Palmer; Christopher S Seet; Martin S Tallman; Xin Wei; Heather Raymon; Priya Sriraman; Stephan Kopytek; Jan Philipp Bewersdorf; Michael R Burgess; Kristen Hege; Wendy Stock
Journal:  Ann Hematol       Date:  2022-01-04       Impact factor: 4.030

5.  CD47 (Cluster of Differentiation 47).

Authors:  Sukhbir Kaur; Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2021

Review 6.  Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.

Authors:  Kyohei Nakamura; Mark J Smyth
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

Review 7.  Are ovarian cancer stem cells the target for innovative immunotherapy?

Authors:  Liang Wang; Tianmin Xu; Manhua Cui
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

8.  Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.

Authors:  Ryo Kazama; Hiroaki Miyoshi; Mai Takeuchi; Kohta Miyawaki; Kazutaka Nakashima; Noriaki Yoshida; Keisuke Kawamoto; Eriko Yanagida; Kyohei Yamada; Takeshi Umeno; Takaharu Suzuki; Koji Kato; Jun Takizawa; Masao Seto; Koichi Akashi; Koichi Ohshima
Journal:  Cancer Sci       Date:  2020-06-29       Impact factor: 6.716

9.  Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.

Authors:  Xuefei Zhou; Xiangrui Liu; Leaf Huang
Journal:  Adv Funct Mater       Date:  2020-11-10       Impact factor: 18.808

10.  Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer.

Authors:  Yan Xu; Ji Li; Bing Tong; Minjiang Chen; Xiaoyan Liu; Wei Zhong; Jing Zhao; Mengzhao Wang
Journal:  ESMO Open       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.